Standard Biotools CFO Kim Hanjoon Alex Sells Over 202,000 Shares in Stock Withholding Transaction

Tax Withholding Triggered by Restricted Stock Unit Vesting

Standard Biotools disclosed that the share disposition by Chief Financial Officer Kim Hanjoon Alex was not a voluntary sale but rather an automatic withholding transaction. The shares were withheld to satisfy tax withholding obligations that arose upon the vesting of restricted stock units that were originally granted to the CFO on August 1, 2025. This RSU grant had been previously reported to the Securities and Exchange Commission in a Form 4 filing dated August 5, 2025, establishing the baseline transaction date and terms.

When employees or executives receive compensation through restricted stock units that vest, tax obligations are triggered at the vesting date. Companies typically allow executives to satisfy these tax withholding requirements through share withholding arrangements, where the company automatically retains a portion of the vested shares at fair market value to cover federal, state, and local tax liabilities. This mechanism protects executives from having to liquidate shares manually and simplifies tax compliance for both the individual and the issuer.

Share Transaction Details and Pricing

The disposition involved 202,476 shares of Standard Biotools common stock executed on July 23, 2026. The shares were withheld at a price of $0.895 per share, which represented the fair market value at the time of the vesting event. This pricing reflects the stock's valuation at the point the tax withholding obligation crystallized, not the date of the original August 2025 grant. The use of a specific price per share demonstrates that the transaction was processed at a defined valuation point tied to the vesting date rather than a range of prices.

The transaction was processed on a direct ownership basis, meaning the CFO maintained direct beneficial ownership of the shares throughout the withholding process. Standard Biotools did not indicate any indirect ownership structures or third-party arrangements related to this transaction. The reporting person's ownership was recorded as direct, which is typical for insider share transactions involving officers of public companies.

Ongoing Beneficial Ownership Position Following the Transaction

Following the completion of the share withholding transaction, CFO Kim Hanjoon Alex maintained beneficial ownership of 2,563,054 shares of Standard Biotools common stock on a direct basis. This remaining ownership position reflects the shares retained after the 202,476-share withholding and represents a significant ongoing equity stake in the company. The filing does not indicate any subsequent transactions or changes to this ownership position as of the disclosure date.

The magnitude of the CFO's retained shareholding suggests a continued financial alignment between executive management and Standard Biotools shareholders. Insider ownership levels are often monitored by equity analysts and institutional investors as an indicator of management confidence in the company's prospects and strategic direction. The CFO's substantial direct ownership position may be relevant to investors evaluating governance structure and incentive alignment within the organization.

Employee Stock Purchase Plan Participation

The disclosure included a notation that the CFO's beneficial ownership total of 2,563,054 shares encompasses 5,000 shares of common stock acquired on May 29, 2026, under Standard Biotools' Employee Stock Purchase Plan. This indicates that the CFO participates in the company's standard employee equity plan alongside the executive compensation arrangements reflected in the RSU program. ESPP participation by senior executives is commonly viewed as a signal of engagement with employee-level equity programs and shareholder interests.

The acquisition of shares under the ESPP on May 29, 2026, occurred prior to the July 23, 2026, withholding transaction covered in this disclosure. The filing structure makes clear that both the ESPP shares and shares from other company equity programs are aggregated in the beneficially owned share count reported to the SEC. Standard Biotools did not disclose the purchase price, discount structure, or other terms of the May 2026 ESPP transaction in this filing.

Officer Certification and Legal Authority

The disclosure was signed on July 27, 2026, three business days after the transaction execution date of July 23, 2026. The Form 4 signature was executed by Tomone Tanaka, identified as attorney-in-fact for CFO Kim Hanjoon Alex. This delegation of signing authority to legal counsel is a common administrative practice for insider transactions and does not alter the validity or legal implications of the filing. The attorney-in-fact arrangement allows executives to delegate the mechanics of regulatory filing compliance to qualified legal representatives while maintaining personal responsibility for the accuracy of reported information.

Standard Biotools confirmed that the reporting person holds the position of Chief Financial Officer, subject to Section 16 reporting obligations under securities law. This classification establishes that the transaction and ongoing ownership position fall within the scope of SEC beneficial ownership disclosure requirements. The CFO's officer status means that any future transactions in company securities will continue to be subject to public reporting within two business days of execution.

Context for Standard Biotools Insider Reporting

Standard Biotools Inc., trading on NASDAQ under ticker LAB, is subject to the insider reporting regime established by Section 16 of the Securities Exchange Act of 1934. Officers, directors, and significant shareholders of public companies must file Forms 4 within two business days of transactions in company securities. The CFO's filing demonstrates compliance with these SEC requirements and provides transparency to public investors regarding changes in insider ownership stakes and executive compensation activities.

The July 2026 transaction represents one data point in the ongoing series of executive compensation and equity transactions at Standard Biotools. The company's filing system creates a cumulative public record of insider activity that can be reviewed by investors, analysts, and market participants interested in understanding management's relationship to company equity. This level of disclosure is mandatory and serves as a foundation for assessing potential insider trading compliance and strategic shareholding patterns.

Tax Withholding as Standard Executive Compensation Practice

The automatic share withholding mechanism used to satisfy the CFO's tax obligations is a standard feature of restricted stock unit programs at public companies. Rather than requiring executives to sell shares independently to raise funds for taxes, companies implement withholding arrangements that execute automatically at vesting. This approach simplifies administration, reduces the likelihood of inadvertent securities law violations, and ensures that tax liabilities are satisfied promptly without requiring executive action during blackout periods or other trading restrictions.

The specific tax withholding approach used in this transaction—retaining shares at fair market value to cover estimated tax obligations—is commonly referred to as a "net settlement" or "net share settlement" arrangement. The filing notation indicates that the withholding obligation arose specifically from the August 1, 2025 RSU grant vesting, confirming that the tax event and the share withholding occurred in the same reporting period separated by eleven months. The delayed vesting period between grant and vesting is typical for RSU programs designed to provide retention incentives and support long-term executive alignment with shareholder interests.

Insider Trading Rules and Reporting Compliance

The Form 4 filing completed by Standard Biotools demonstrates compliance with SEC Rule 16a-3, which establishes the requirement for officers to report beneficial ownership changes within two business days. The disclosure was filed on July 27, 2026, three business days after the July 23, 2026 transaction, indicating that the company submitted the filing within the regulatory window. Timely Form 4 filings are essential for maintaining compliance with securities regulations and ensuring that public investors have access to current insider ownership information.

The filing provides detailed transaction codes, pricing information, and ownership totals that allow regulatory authorities and the investing public to verify the accuracy of insider reporting. The disclosure explicitly notes the connection between the withholding transaction and the original August 2025 RSU grant, creating an audit trail that documents the relationship between compensation awards and equity transactions. This level of transparency is consistent with SEC expectations for executive reporting and supports investor confidence in the integrity of public company information disclosure.